Search research articles
Contact Us
Filters
Showing results (31-40 of 36) with videos related to
Page
of 4
Sort By:
You have reached the last page of results.
This site can display upto 36 results.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
May 20, 1998
Ninety-six-hour infusional paclitaxel as salvage therapy of ovarian cancer patients previously failing treatment with 3-hour or 24-hour paclitaxel infusion regimens
M Markman, P G Rose, E Jones, et al.
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America
|
March 21, 1998
Human papillomavirus and disease status following therapy for cervical cancer
E R Unger, S D Vernon, R Nisenbaum, et al.
Cancer
|
December 15, 1995
Cervical cancer survival in a high risk urban population
W W Thoms, E R Unger, P R Johnson, et al.
Sexually Transmitted Infections
|
January 1, 2000
Association of human papillomavirus with HIV and CD4 cell count in women with high or low numbers of sex partners
M A Piper, S T Severin, S Z Wiktor, et al.
Sexually Transmitted Infections
|
January 1, 2000
HIV and human papillomavirus as independent risk factors for cervical neoplasia in women with high or low numbers of sex partners
S D Vernon, E R Unger, M A Piper, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
January 1, 1997
Phase I trial and pharmacologic trial of sequences of paclitaxel and topotecan in previously treated ovarian epithelial malignancies: a Gynecologic Oncology Group study
S O'Reilly, G F Fleming, S D Barker, et al.
Page
of 4
Search research articles
Search
Showing results (31-40 of 36) with videos related to
Sort By:
Page
of 4
You have reached the last page of results.
This site can display upto 36 results.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
May 20, 1998
Ninety-six-hour infusional paclitaxel as salvage therapy of ovarian cancer patients previously failing treatment with 3-hour or 24-hour paclitaxel infusion regimens
M Markman, P G Rose, E Jones, et al.
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America
|
March 21, 1998
Human papillomavirus and disease status following therapy for cervical cancer
E R Unger, S D Vernon, R Nisenbaum, et al.
Cancer
|
December 15, 1995
Cervical cancer survival in a high risk urban population
W W Thoms, E R Unger, P R Johnson, et al.
Sexually Transmitted Infections
|
January 1, 2000
Association of human papillomavirus with HIV and CD4 cell count in women with high or low numbers of sex partners
M A Piper, S T Severin, S Z Wiktor, et al.
Sexually Transmitted Infections
|
January 1, 2000
HIV and human papillomavirus as independent risk factors for cervical neoplasia in women with high or low numbers of sex partners
S D Vernon, E R Unger, M A Piper, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
January 1, 1997
Phase I trial and pharmacologic trial of sequences of paclitaxel and topotecan in previously treated ovarian epithelial malignancies: a Gynecologic Oncology Group study
S O'Reilly, G F Fleming, S D Barker, et al.
Page
of 4